Welcome to my annual player review series, where I dive into the Edmonton Oilers season player-by-player. We’ll look back at the season that was, what kind of impact each player had, and what we ...

Summary Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential.

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...

Amgen stock (NASDAQ:AMGN) declined 6% on Monday, June 23, 2025, following the release of mid-stage clinical trial results for its long-acting obesity drug candidate, MariTide.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen announced detailed tolerability data from phase 1 and phase 2 studies of obesity drug candidate maritide, and management disclosed the design of its two ongoing phase 3 obesity studies.

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a mid-stage trial, as the company plans to adjust dosing.

The dust is beginning to settle after the Edmonton Oilers lost in the Stanley Cup Final for the second year in a row. And of course, when you take a step back, there are some silver linings, and ...

Penguins A to Z: Vasily Ponomarev's once bright NHL future is now in doubt Seth Rorabaugh | Thursday, June 12, 2025 6:01 a.m.

Ponomarev signed a three-year contract with the KHL's Avangard Omsk on Wednesday, per Seth Rorabaugh of Tribune-Review Sports. Ponomarev had 15 goals, 41 points and 44 PIM across 55 regular-season ...